164 related items for PubMed ID: 37423157
1. Serum IL-41 might be a biomarker for IVIG resistance and coronary artery lesions in Kawasaki disease.
Duan Y, Li H, Luo D, Jiang J, Liu B, Li G.
Int Immunopharmacol; 2023 Sep; 122():110600. PubMed ID: 37423157
[Abstract] [Full Text] [Related]
2. Predictive value of monocyte to HDL-C ratio for coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease.
Wang JR, Zhao HZ, Chang LJ, Xu X, Gao Y, Li M, Kong QY, Wang MM, Zhao CF.
Eur J Pediatr; 2023 Oct; 182(10):4399-4406. PubMed ID: 37480545
[Abstract] [Full Text] [Related]
3. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
Xie T, Wang Y, Fu S, Wang W, Xie C, Zhang Y, Gong F.
Pediatr Rheumatol Online J; 2017 Mar 21; 15(1):17. PubMed ID: 28320400
[Abstract] [Full Text] [Related]
4. Serum amyloid A as a biomarker for immunoglobulin resistance in Kawasaki disease.
Huang XB, Zhao S, Liu ZY, Xu YY, Deng F.
Ann Med; 2023 Mar 21; 55(2):2264315. PubMed ID: 37870383
[Abstract] [Full Text] [Related]
5. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J, Qi Y, Xie C, Zhang Y.
Arthritis Rheum; 2013 Mar 21; 65(3):805-14. PubMed ID: 23440694
[Abstract] [Full Text] [Related]
6. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
Postgrad Med; 2018 May 21; 130(4):442-447. PubMed ID: 29745742
[Abstract] [Full Text] [Related]
7. The role of serum lipid in predicting coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease: a cohort study.
Zhang H, Cai J, Zhang R, Shuai S, Tang M, Ju R, Hu Y, Zuo T, Yang Y.
J Int Med Res; 2024 May 21; 52(5):3000605241252115. PubMed ID: 38713460
[Abstract] [Full Text] [Related]
8. Association between serum miR-221-3p and intravenous immunoglobulin resistance in children with Kawasaki disease.
Jing F, Weng H, Pei Q, Zhang J, Liu R, Yi Q.
Clin Exp Med; 2022 Nov 21; 22(4):621-628. PubMed ID: 35039938
[Abstract] [Full Text] [Related]
9. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm.
Wu Y, Liu FF, Xu Y, Wang JJ, Samadli S, Wu YF, Liu HH, Chen WX, Luo HH, Zhang DD, Wei W, Hu P.
Clin Exp Med; 2019 May 21; 19(2):173-181. PubMed ID: 30617865
[Abstract] [Full Text] [Related]
10. A comparison of serum IL6 and CRP levels with respect to coronary changes and treatment response in Kawasaki disease patients: a prospective study.
Nandi A, Pal P, Basu S.
Rheumatol Int; 2019 Oct 21; 39(10):1797-1801. PubMed ID: 31302740
[Abstract] [Full Text] [Related]
11. Predictive Value of Serum Lipid for Intravenous Immunoglobulin Resistance and Coronary Artery Lesion in Kawasaki Disease.
Shao S, Zhou K, Liu X, Liu L, Wu M, Deng Y, Duan H, Li Y, Hua Y, Wang C.
J Clin Endocrinol Metab; 2021 Sep 27; 106(10):e4210-e4220. PubMed ID: 33837779
[Abstract] [Full Text] [Related]
12. [Expression of interleukin-17A in serum of children with intravenous immunoglobulin-resistant Kawasaki disease and its clinical significance].
Li SY, Ding Y.
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Mar 15; 25(3):244-249. PubMed ID: 36946157
[Abstract] [Full Text] [Related]
13. Clinical indicators combined with S100A12/TLR2 signaling molecules to establish a new scoring model for coronary artery lesions in Kawasaki disease.
Wu Y, Wang S, Zhou Y, Yang Y, Li S, Yin W, Ding Y.
PLoS One; 2023 Mar 15; 18(10):e0292653. PubMed ID: 37824465
[Abstract] [Full Text] [Related]
14. Risk factors of intravenous immunoglobulin resistance and coronary arterial lesions in Turkish children with Kawasaki disease.
Türkuçar S, Yıldız K, Acarı C, Dundar HA, Kır M, Ünsal E.
Turk J Pediatr; 2020 Mar 15; 62(1):1-9. PubMed ID: 32253860
[Abstract] [Full Text] [Related]
15. Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy.
Liu J, Ye B, Su D, Qin S, Zhao W, Pang Y.
Clin Rheumatol; 2023 Jan 15; 42(1):167-177. PubMed ID: 36129563
[Abstract] [Full Text] [Related]
16. Predictive value of albumin for intravenous immunoglobulin resistance in a large cohort of Kawasaki disease patients.
Zhang R, Shuai S, Zhang H, Cai J, Cui N, Tang M, Xing S, Gao Y, Liu X, Yang X.
Ital J Pediatr; 2023 Jun 25; 49(1):78. PubMed ID: 37357258
[Abstract] [Full Text] [Related]
17. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
Pediatr Infect Dis J; 2018 Oct 25; 37(10):976-980. PubMed ID: 29461447
[Abstract] [Full Text] [Related]
18. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
Iwashima S, Kimura M, Ishikawa T, Ohzeki T.
Clin Drug Investig; 2011 Oct 25; 31(3):191-9. PubMed ID: 21456105
[Abstract] [Full Text] [Related]
19. Interleukin-18 and coronary artery lesions in patients with Kawasaki disease.
Weng KP, Hsieh KS, Huang SH, Ou SF, Lai TJ, Tang CW, Lin CC, Ho TY, Liou HH, Ger LP.
J Chin Med Assoc; 2013 Aug 25; 76(8):438-45. PubMed ID: 23769880
[Abstract] [Full Text] [Related]
20. Value of C-reactive protein/albumin ratio in predicting intravenous immunoglobulin-resistant Kawasaki disease- a data from multi-institutional study in China.
Li G, Wang T, Gou Y, Zeng R, Liu D, Duan Y, Liu B.
Int Immunopharmacol; 2020 Dec 25; 89(Pt A):107037. PubMed ID: 33242833
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
